Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects
European Journal of Clinical Pharmacology1981Vol. 21(2), pp. 127–135
Citations Over TimeTop 14% of 1981 papers
John W. A. Findlay, J. Van Wyck Fleet, P Smith, Robert F. Butz, M L Hinton, Martin Blum, David H. Schroeder
Related Papers
- → Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model(2017)290 cited
- → Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling(2022)12 cited
- → A physiologically-based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K+-competitive acid blocker(2019)7 cited
- → Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers(2018)6 cited
- → An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers(2020)12 cited